Sinphar Pharmaceutical Co.,Ltd. (1734.TW)
TWD 31.55
(-0.94%)
TWD 31.55
(-0.94%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 839.19 Million TWD | 13.86% |
| 2022 | 737.01 Million TWD | 5.68% |
| 2021 | 697.39 Million TWD | 2.34% |
| 2020 | 681.44 Million TWD | 20.18% |
| 2019 | 567 Million TWD | 16.18% |
| 2018 | 488.05 Million TWD | -6.58% |
| 2017 | 522.42 Million TWD | -14.58% |
| 2016 | 611.56 Million TWD | -12.33% |
| 2015 | 697.55 Million TWD | -19.06% |
| 2014 | 861.87 Million TWD | 17.33% |
| 2013 | 734.55 Million TWD | 41.68% |
| 2012 | 518.44 Million TWD | 17.67% |
| 2011 | 440.59 Million TWD | 4.86% |
| 2010 | 420.16 Million TWD | 4.92% |
| 2009 | 400.48 Million TWD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 822.16 Million TWD | 2.39% |
| 2024 Q1 | 839.21 Million TWD | 0.0% |
| 2023 FY | 839.19 Million TWD | 13.86% |
| 2023 Q4 | 839.19 Million TWD | 2.72% |
| 2023 Q3 | 816.98 Million TWD | 3.6% |
| 2023 Q1 | 798.96 Million TWD | 8.41% |
| 2023 Q2 | 788.57 Million TWD | -1.3% |
| 2022 Q3 | 750.24 Million TWD | 2.98% |
| 2022 Q1 | 695.31 Million TWD | -0.3% |
| 2022 FY | 737.01 Million TWD | 5.68% |
| 2022 Q4 | 737.01 Million TWD | -1.76% |
| 2022 Q2 | 728.55 Million TWD | 4.78% |
| 2021 Q1 | 686.44 Million TWD | 0.73% |
| 2021 Q4 | 697.39 Million TWD | -4.55% |
| 2021 FY | 697.39 Million TWD | 2.34% |
| 2021 Q3 | 730.63 Million TWD | 2.87% |
| 2021 Q2 | 710.27 Million TWD | 3.47% |
| 2020 Q3 | 679.17 Million TWD | 1.38% |
| 2020 FY | 681.44 Million TWD | 20.18% |
| 2020 Q4 | 681.44 Million TWD | 0.33% |
| 2020 Q1 | 583.42 Million TWD | 2.9% |
| 2020 Q2 | 669.95 Million TWD | 14.83% |
| 2019 Q2 | 558.7 Million TWD | 7.65% |
| 2019 FY | 567 Million TWD | 16.18% |
| 2019 Q4 | 567 Million TWD | 3.52% |
| 2019 Q3 | 547.71 Million TWD | -1.97% |
| 2019 Q1 | 518.97 Million TWD | 6.34% |
| 2018 Q4 | 488.05 Million TWD | -11.07% |
| 2018 Q1 | 535.77 Million TWD | 2.55% |
| 2018 Q2 | 537.49 Million TWD | 0.32% |
| 2018 FY | 488.05 Million TWD | -6.58% |
| 2018 Q3 | 548.83 Million TWD | 2.11% |
| 2017 Q4 | 522.42 Million TWD | -11.0% |
| 2017 FY | 522.42 Million TWD | -14.58% |
| 2017 Q2 | 583.31 Million TWD | -1.67% |
| 2017 Q3 | 587 Million TWD | 0.63% |
| 2017 Q1 | 593.21 Million TWD | -3.0% |
| 2016 Q1 | 706.07 Million TWD | 1.22% |
| 2016 Q4 | 611.56 Million TWD | -5.03% |
| 2016 Q2 | 701.38 Million TWD | -0.66% |
| 2016 Q3 | 643.97 Million TWD | -8.19% |
| 2016 FY | 611.56 Million TWD | -12.33% |
| 2015 Q4 | 697.55 Million TWD | -11.0% |
| 2015 Q3 | 783.76 Million TWD | 2.27% |
| 2015 Q1 | 821.96 Million TWD | -4.63% |
| 2015 Q2 | 766.33 Million TWD | -6.77% |
| 2015 FY | 697.55 Million TWD | -19.06% |
| 2014 Q2 | 733.89 Million TWD | 0.03% |
| 2014 Q3 | 813.77 Million TWD | 10.88% |
| 2014 FY | 861.87 Million TWD | 17.33% |
| 2014 Q4 | 861.87 Million TWD | 5.91% |
| 2014 Q1 | 733.67 Million TWD | -0.12% |
| 2013 Q4 | 734.55 Million TWD | 30.96% |
| 2013 FY | 734.55 Million TWD | 41.68% |
| 2013 Q2 | 617.38 Million TWD | 6.09% |
| 2013 Q1 | 581.91 Million TWD | 12.24% |
| 2013 Q3 | 560.9 Million TWD | -9.15% |
| 2012 Q2 | 423.22 Million TWD | -2.95% |
| 2012 FY | 518.44 Million TWD | 17.67% |
| 2012 Q1 | 436.08 Million TWD | -1.02% |
| 2012 Q3 | 436.99 Million TWD | 3.25% |
| 2012 Q4 | 518.44 Million TWD | 18.64% |
| 2011 Q4 | 440.59 Million TWD | 1.89% |
| 2011 Q1 | 386.94 Million TWD | -7.91% |
| 2011 Q2 | 409.21 Million TWD | 5.76% |
| 2011 FY | 440.59 Million TWD | 4.86% |
| 2011 Q3 | 432.44 Million TWD | 5.67% |
| 2010 Q4 | 420.16 Million TWD | 0.0% |
| 2010 FY | 420.16 Million TWD | 4.92% |
| 2009 FY | 400.48 Million TWD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Apex Biotechnology Corp. | 747.71 Million TWD | -12.235% |
| Panion & Bf Biotech Inc. | 538.09 Million TWD | -55.956% |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 1.21 Billion TWD | 30.704% |
| GenMont Biotech Incorporation | 88.11 Million TWD | -852.353% |
| Abnova (Taiwan) Corporation | 408.3 Million TWD | -105.533% |
| Adimmune Corporation | 526.4 Million TWD | -59.42% |
| Tanvex BioPharma, Inc. | 108.28 Million TWD | -674.986% |
| Polaris Group | 36.35 Million TWD | -2208.332% |
| Energenesis Biomedical CO.,LTD. | 733 Thousand TWD | -114387.585% |
| UnicoCell Biomed Co., Ltd. | 5.45 Million TWD | -15295.23% |
| PELL Bio-Med Technology Co. Ltd. | 3.76 Million TWD | -22201.196% |